AML
Conference Coverage
VIDEO: High-intensity conditioning stands ground in MDS, AML
Video
VIDEO: Midostaurin hits mark in FLT3-mutated AML
The oral multikinase inhibitor midostaurin improved overall survival by 23% when added to standard chemotherapy and given as maintenance therapy...
News
Team identifies potential biomarkers for AML therapy
Photo by Kristin Gladney New research published in Cell Reports has revealed biomarkers that may help predict which acute myeloid leukemia (AML)...
News
Expert panel issues guidelines for treatment of hematologic cancers in pregnancy
The guidelines aim to ensure that timely treatment of the cancers is not delayed in pregnant women. While rare, hematologic malignancies in...
News
A different approach to AML treatment
Image by Tom Ellenberger PARP inhibitors could prove useful for treating aggressive acute myeloid leukemia (AML), according to preclinical...
News
Berry-derived compound can fight AML
A compound derived from the berries of the Bloodhorn tree has demonstrated activity against acute myeloid leukemia (AML), according to preclinical...
News
RIC can improve HSCT outcomes in older AML patients
Photo by Chad McNeeley Results of a phase 2 study suggest that reduced-intensity conditioning (RIC) may allow older patients with acute myeloid...
News
EC expands indication for azacitidine in AML
The European Commission (EC) has expanded the approved indication for azacitidine for injection (Vidaza) in acute myeloid leukemia (AML). Now,...
News
New test could help fight leukemia
Image courtesy of NIAID Researchers say they have developed a test that can reveal how the immune system would respond to vaccines for leukemia...
News
Group identifies potential target for AML
marrow cells generated by AE Image courtesy of The Rockefeller University Preclinical research has revealed a potential therapeutic target for...
News
Novel compound could treat leukemia
A small-molecule compound that has previously shown activity against Ewing sarcoma and prostate cancer may fight leukemia as well, according to...